PL407153A1 - Pochodne 2',5'-dideoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób ich wytwarzania i zastosowanie - Google Patents

Pochodne 2',5'-dideoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób ich wytwarzania i zastosowanie

Info

Publication number
PL407153A1
PL407153A1 PL407153A PL40715314A PL407153A1 PL 407153 A1 PL407153 A1 PL 407153A1 PL 407153 A PL407153 A PL 407153A PL 40715314 A PL40715314 A PL 40715314A PL 407153 A1 PL407153 A1 PL 407153A1
Authority
PL
Poland
Prior art keywords
dideoxy
preparation
derivatives
cytotoxic effect
fluorouridine derivatives
Prior art date
Application number
PL407153A
Other languages
English (en)
Other versions
PL225349B1 (pl
Inventor
Lech Celewicz
Karol Kacprzak
Marta Lewandowska
Piotr Ruszkowski
Natalia Kleczewska
Original Assignee
Uniwersytet Im. Adama Mickiewicza W Poznaniu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Im. Adama Mickiewicza W Poznaniu filed Critical Uniwersytet Im. Adama Mickiewicza W Poznaniu
Priority to PL407153A priority Critical patent/PL225349B1/pl
Priority to CA2888015A priority patent/CA2888015C/en
Priority to EP14716997.3A priority patent/EP3105242A1/en
Priority to PCT/PL2014/050010 priority patent/WO2015041550A1/en
Priority to JP2015544028A priority patent/JP5924797B2/ja
Priority to US14/413,618 priority patent/US9605017B2/en
Publication of PL407153A1 publication Critical patent/PL407153A1/pl
Priority to CN201410613758.2A priority patent/CN104829669A/zh
Publication of PL225349B1 publication Critical patent/PL225349B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Przedmiotem wynalazku są nowe pochodne 2',5'-dideoksy-5-fluorourydyny o ogólnym wzorze 1, gdzie R1 oznacza fragment alkaloidu chinowca o zdefiniowanej konfiguracji absolutnej na atomach C-8 i C-9, a także sposób wytwarzania tych pochodnych. Wynalazek obejmuje również sole związków o wzorze ogólnym 1 i zastosowanie pochodnych 2',5'-dideoksy-5-fluorourydyny o ogólnym wzorze 1 w terapii przeciwnowotworowej raka piersi, szyjki macicy, płuca oraz nosogardzieli.
PL407153A 2014-02-12 2014-02-12 Pochodne 2’,5’-dideoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób ich wytwarzania i zastosowanie PL225349B1 (pl)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PL407153A PL225349B1 (pl) 2014-02-12 2014-02-12 Pochodne 2’,5’-dideoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób ich wytwarzania i zastosowanie
CA2888015A CA2888015C (en) 2014-02-12 2014-03-04 2',5'-dideoxy-5-fluorouridine derivatives having cytotoxic activity, a process for the manufacture thereof and application thereof
EP14716997.3A EP3105242A1 (en) 2014-02-12 2014-03-04 2',5'-dideoxy-5-fluorouridine derivatives having cytotoxic activity, a process for the manufacture thereof and application thereof
PCT/PL2014/050010 WO2015041550A1 (en) 2014-02-12 2014-03-04 2',5'-dideoxy-5-fluorouridine derivatives having cytotoxic activity, a process for the manufacture thereof and application thereof
JP2015544028A JP5924797B2 (ja) 2014-02-12 2014-03-04 細胞毒性を有する２’，５’−ジデオキシ−５−フルオロウリジン誘導体、それらの製造プロセスおよびそれらの利用
US14/413,618 US9605017B2 (en) 2014-02-12 2014-03-04 2′, 5′-dideoxy-5-fluorouridine derivatives having cytotoxic activity, a process for the manufacture thereof and application thereof
CN201410613758.2A CN104829669A (zh) 2014-02-12 2014-11-04 具有细胞毒活性的2’,5’-双脱氧-5-氟尿嘧啶核苷衍生物、生产方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL407153A PL225349B1 (pl) 2014-02-12 2014-02-12 Pochodne 2’,5’-dideoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób ich wytwarzania i zastosowanie

Publications (2)

Publication Number Publication Date
PL407153A1 true PL407153A1 (pl) 2014-09-01
PL225349B1 PL225349B1 (pl) 2017-03-31

Family

ID=50478927

Family Applications (1)

Application Number Title Priority Date Filing Date
PL407153A PL225349B1 (pl) 2014-02-12 2014-02-12 Pochodne 2’,5’-dideoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób ich wytwarzania i zastosowanie

Country Status (7)

Country Link
US (1) US9605017B2 (pl)
EP (1) EP3105242A1 (pl)
JP (1) JP5924797B2 (pl)
CN (1) CN104829669A (pl)
CA (1) CA2888015C (pl)
PL (1) PL225349B1 (pl)
WO (1) WO2015041550A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CN109942547B (zh) * 2019-05-06 2021-08-27 河南师范大学 具有生物活性的新型喹啉取代三氮唑类化合物及其合成方法和应用
CN119161303B (zh) * 2024-03-20 2025-02-11 烟台大学 一种含氮杂环化合物在制备抗菌药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2587647B2 (ja) * 1987-09-07 1997-03-05 大鵬薬品工業株式会社 ３′−置換トリアゾール−２′，３′−ジデオキシ−５−置換ピリミジンヌクレオシド誘導体
TWI298067B (en) 2002-01-31 2008-06-21 Daiso Co Ltd New optically active compound, method for kinetic resolution of carbonic acid derivatives and catalyst thereof

Also Published As

Publication number Publication date
US9605017B2 (en) 2017-03-28
EP3105242A1 (en) 2016-12-21
PL225349B1 (pl) 2017-03-31
CA2888015C (en) 2016-05-24
WO2015041550A1 (en) 2015-03-26
CA2888015A1 (en) 2015-03-26
JP2016500101A (ja) 2016-01-07
US20160244473A1 (en) 2016-08-25
JP5924797B2 (ja) 2016-05-25
CN104829669A (zh) 2015-08-12

Similar Documents

Publication Publication Date Title
CY1122712T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
MX2018011792A (es) Compuestos de pirrolotriazina como inhibidores de tyro3, axl y mer (tam).
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
EA201990833A1 (ru) Соединение пиридина
TW201613603A (en) Pharmaceutical preparation
MX376283B (es) Compuestos de imidazopiridazina.
MX390945B (es) Compuestos para el tratamiento de tnbc.
PL407153A1 (pl) Pochodne 2',5'-dideoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób ich wytwarzania i zastosowanie
CY1122375T1 (el) Συμπυκνωμενα με τετραϋδροφουρανιο αμινοϋδροθειαζινικα αναλογα τα οποια ειναι χρησιμα στη θεραπεια της νοσου toy alzheimer
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
PL407152A1 (pl) Pochodne 2',3'-dideoksy-5-fluorourydyny, sposób ich wytwarzania i zastosowanie
MY183757A (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EA201991208A1 (ru) Способы лечения множественного остеохондроматоза (мо)
PH12017501134A1 (en) Fumagillol derivatives
PH12017501063A1 (en) Compounds for the treatment of cancer
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam
IN2013MU03838A (pl)
MX2015017276A (es) Derivados de hiperforina y su uso en la enfermedad de alzheimer.
EA201992471A2 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b